Get the Stockscreener App
149.97
3.95%
5.70
After Hours:
148.83
-1.14
-0.76%
Davita Inc stock is traded at $149.97, with a volume of 1.84M.
It is up +3.95% in the last 24 hours and up +36.21% over the past month.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
See More
Previous Close:
$144.27
Open:
$144.34
24h Volume:
1.84M
Relative Volume:
1.71
Market Cap:
$10.03B
Revenue:
$12.82B
Net Income/Loss:
$936.34M
P/E Ratio:
13.96
EPS:
10.74
Net Cash Flow:
$1.47B
1W Performance:
+0.50%
1M Performance:
+36.21%
6M Performance:
+13.54%
1Y Performance:
-12.81%
1-Day Range:
$144.34
$152.76
1-Week Range:
$136.19
$152.76
52-Week Range:
$101.00
$178.38
Davita Inc Stock (DVA) Company Profile
Name
Davita Inc
Sector
Industry
Phone
310-536-2668
Address
2000 16TH STREET, DENVER, CO
Compare DVA vs HCA, THC, UHS, FMS, ENSG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DVA
Davita Inc
|
149.97 | 9.64B | 12.82B | 936.34M | 1.47B | 10.74 |
|
HCA
Hca Healthcare Inc
|
535.22 | 118.85B | 75.60B | 7.78B | 7.69B | 28.38 |
|
THC
Tenet Healthcare Corp
|
232.26 | 19.89B | 20.69B | 2.40B | 1.55B | 15.62 |
|
UHS
Universal Health Services Inc
|
234.05 | 14.45B | 16.08B | 1.20B | 1.06B | 17.82 |
|
FMS
Fresenius Medical Care Ag Adr
|
24.46 | 13.94B | 21.23B | 924.30M | 2.22B | 1.2272 |
|
ENSG
Ensign Group Inc
|
214.41 | 12.32B | 4.11B | 239.98M | 193.10M | 4.12 |
Davita Inc Stock (DVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-24 | Initiated | Barclays | Equal Weight |
| Aug-07-23 | Upgrade | UBS | Neutral → Buy |
| Nov-01-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-31-22 | Downgrade | UBS | Buy → Neutral |
| Aug-19-22 | Resumed | UBS | Buy |
| Jun-21-22 | Reiterated | BofA Securities | Underperform |
| Sep-10-21 | Initiated | Cowen | Market Perform |
| Aug-12-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-26-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-05-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-24-20 | Upgrade | Goldman | Neutral → Buy |
| Nov-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-25-19 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-11-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-26-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-19 | Upgrade | UBS | Sell → Neutral |
| Jan-03-19 | Initiated | Deutsche Bank | Buy |
| Dec-14-18 | Initiated | Barclays | Overweight |
| Nov-28-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Nov-16-18 | Initiated | UBS | Sell |
| Nov-08-18 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Sep-13-18 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-04-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-12-17 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-11-17 | Upgrade | Citigroup | Neutral → Buy |
| Dec-07-17 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-08-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Oct-09-17 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-26-17 | Downgrade | Jefferies | Buy → Hold |
| Dec-13-16 | Downgrade | Robert W. Baird | Outperform → Neutral |
View All
Davita Inc Stock (DVA) Latest News
The Dialysis Renaissance: How DaVita (DVA) Conquered the GLP-1 Fear and Defined Healthcare Resilience in 2026 - FinancialContent
Gains Report: Will DaVita Inc benefit from seasonalityJuly 2025 PostEarnings & Long-Term Capital Growth Strategies - baoquankhu1.vn
Palmetto Grain Brokerage - Palmetto Grain Brokerage
DaVita Stock: Is Wall Street Bullish or Bearish? - Barchart.com
The 5 Most Interesting Analyst Questions From DaVita’s Q4 Earnings Call - TradingView
2 Warren Buffett Stocks to Buy Hand Over Fist in 2026 and 1 to Avoid - The Motley Fool
DaVita Dipped 6% After Big Run-Up: Why Analysts See a Path to $210 in 2026 - TIKR.com
DaVita (DVA) Surges as Top Healthcare Gainer in S&P 500 - GuruFocus
DaVita (DVA) Is Up 28.8% After Strong 2026 Guidance And Heavy BuybacksWhat's Changed - simplywall.st
Guidance Update: Will DaVita Inc stock benefit from M AMarket Risk Report & Weekly Chart Analysis and Guides - baoquankhu1.vn
DaVita Inc. $DVA Shares Sold by BI Asset Management Fondsmaeglerselskab A S - MarketBeat
DaVita, Elara deal could signal new take on kidney, home care - Modern Healthcare News
DaVita (NYSE:DVA) Shares Down 4.5%Time to Sell? - MarketBeat
DaVita (NYSE:DVA) Upgraded by Zacks Research to "Strong-Buy" Rating - MarketBeat
Even With A 30% Surge, Cautious Investors Are Not Rewarding DaVita Inc.'s (NYSE:DVA) Performance Completely - simplywall.st
DaVita Inc. $DVA Shares Sold by Allianz Asset Management GmbH - MarketBeat
Should Value Investors Buy DaVita (DVA) Stock? - Yahoo Finance
Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term - Yahoo Finance
DaVita Inc. (NYSE:DVA) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
DaVita Inc. $DVA Shares Sold by Strs Ohio - MarketBeat
DaVita Links IKC Profitability With Elara Home Care To Recast Growth - Yahoo Finance
DaVita (DVA) Margin Compression To 5.3% Challenges Bullish Valuation Narratives - Sahm
Here's why you should hold DaVita stock in your portfolio for now - MSN
DaVita stock price pops again as 2026 outlook fuels fresh Wall Street targets - TechStock²
UBS Raises Price Target for DaVita (DVA) to $190, Maintains Buy Rating | DVA Stock News - GuruFocus
DaVita Projects Significant EPS Growth Amid Strategic Expansion - StocksToTrade
DaVita stock price target raised to $190 from $186 at UBS on growth outlook - Investing.com Australia
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Boston Scientific (BSX) and DaVita (DVA) - The Globe and Mail
Lawsuit Investigation: Did DaVita Violate Patients’ Online Privacy? - ClassAction.org
Why Is DaVita (DVA) Stock Rocketing Higher Today - The Globe and Mail
DVA Q4 Deep Dive: Clinical Initiatives and Integrated Care Drive Outlook Amid Margin Compression - The Globe and Mail
Dallas Team Featured as Litigator of the Week - Winston & Strawn
Research Alert: CFRA Maintains Hold View On Shares Of Davita Inc. - 富途牛牛
Is DaVita stock underperforming the Dow? - MSN
Ares, DaVita to invest in home health provider Elara Caring By Investing.com - Investing.com India
DaVita Home Care Partnership Puts Valuation And Risk Profile In Focus - Sahm
DaVita’s Q4 Earnings Triumph Sparks Market Interest - timothysykes.com
DaVita Inc. stock outperforms competitors on strong trading day - MarketWatch
DaVita (DVA) Shares Surge on Strong Q4 Results and Optimistic 20 - GuruFocus
DaVita Stock Surges as Q4 Earnings Exceed Expectations - StocksToTrade
DaVita Celebrates Strong Earnings as Strategic Investments Boost Future Outlook - timothysykes.com
Ares, DaVita Make Strategic Investment in Elara Caring - Hospice News
DaVita climbs as Q4 beat outshines Berkshire Hathaway insider sale - Seeking Alpha
Explore DaVita Within Dow Jones Industrial Average Healthcare Space - Kalkine Media
DaVita (DVA) Shares Surge Over 21% Amid Market Moves - GuruFocus
DaVita stock price jumps nearly 20% as 2026 profit outlook beats Street; what investors watch next - TechStock²
What Sent DaVita Stock Soaring On Tuesday? - Finviz
DaVita Inc Stock Soars 25% After DaVita Beats Q4 Results And Raises 2026 Outlook - Nasdaq
DaVita Stock Rallies On Profit Beat, Confident 2026 View - Benzinga
DaVita Stock Soars as Q4 Earnings and Strategy Surpass Expectations - StocksToTrade
Silver Surges Over 15%; Pfizer Earnings Top Views - Benzinga
Davita Inc Stock (DVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
1.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):